This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

29 Oct 2012

ImunoGen highlights benefits of T-DM1

ImmunoGen believes its new TAP cancer drug has large potential in the treatment of early stage breast and gastric cancers.


Biopharma company ImmunoGen has taken the opportunity to highlight the commercial potential it sees in its cancer drug T-DM1.

Related News